NEW YORK, Aug. 4, 2022 /PRNewswire/ -- The global monoclonal antibody therapy market is expected to clock US$ ~523 billion by 2030 owing to the rising incidence of chronic diseases, increased use of hyphenated techniques in monoclonal antibody therapy states Growth Plus Reports
The rising occurrence of chronic diseases such as cancer, autoimmune diseases like Crohn's disease, rheumatoid arthritis, ulcerative colitis, and Alzheimer's disease are leading to the adoption of monoclonal antibody therapy. Pharmaceuticals and biotechnology companies are aggressively investing in the research and development of innovative biologics and regulatory bodies like the FDA approving these compounds are all driving the monoclonal antibody therapy market.
The global monoclonal antibody therapy market has been analyzed from five different perspectives – type, disease area, production type, end-user, and region.
Request a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/monoclonal-antibody-therapy-market/7736
Report Scope & Segmentation:
Market Size in 2021
USD ~ 175.5 billion
Revenue forecast in 2030
USD ~ 523 billion
CAGR of ~ 12.9%from 2022 to 2030
Base year for estimation
Type, Disease Area, Disease Area, End-user
North America, Europe, Asia Pacific, and the Rest of the World (ROW)
Excerpts from 'By Type Segmentation'
The global monoclonal antibody therapy market has been segmented majorly into four distinct types:
- Human mAb
- Chimeric mAb
- Humanized mAb
- Murine mAb
The market for mAb therapy around the world is dominated by human mAb. Due to the high demand for Humira, which is used to treat a variety of illnesses including ulcerative colitis, arthritis, and Crohn's disease, this dominance is the result. It was the first monoclonal antibody that the FDA had approved. The market for human mAb is also driven by the expansion through technology amalgamation.
However, as per analysis, due to increased investment in research by pharmaceutical firms and the rise in the utilization of humanized mAb therapeutics, the humanized antibody market is anticipated to experience growth during the forecast period.
Browse the full report here: https://growthplusreports.com/report/monoclonal-antibody-therapy-market/7736
Excerpts from 'By Region Segmentation'
The global monoclonal antibody therapy market has been segmented into:
- North America
- Asia Pacific
- Rest of the World (RoW)
In terms of revenue, North America currently holds the largest revenue share. This attributes to the presence of major key players and products getting approved on a larger scale. Furthermore, industries spending on R&D activities and support from the government in terms of research have paved way for the development of novel monoclonal antibody therapeutics. Also, improved healthcare infrastructure has enhanced the treatment accessibility for the population hence leading to the rising demand for mAb products.
However, it has been also analyzed that the Asia Pacific would experience a rapid growth rate in the forecast period. One of the biggest reasons is that most of the cases of chronic diseases like cancer etc. are concentrated in this region, which is increasing the burden on the economy. Hence, governments in this region are taking measures to come up with cost-effective treatments. The rising medical tourism is also bringing opportunities for many pharmaceutical companies to launch their products. These factors, therefore, are driving the monoclonal antibody therapy market.
Excerpts from 'Competitive Landscape'
Some of the prominent players operating in the monoclonal antibody therapy market are:
- F. Hoffman-La Roche Ltd
- Bayer AG
- Novo Nordisk A/S
- Thermo Fisher Scientific Inc
- Regeneron Pharmaceuticals Inc
- AstraZeneca plc
- Sanofi SA
- Abbott Laboratories
- Eli Lilly & Company
- Mylan N.V
- GlaxoSmithKline Plc
- Merck KgaA
- Among others
Table of Content:
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecasted Years – 2022 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trend (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Request for customization of this research report at: https://growthplusreports.com/report/monoclonal-antibody-therapy-market/7736
Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
SOURCE Growth Plus Reports